KATIE VERB

health care reform and the needs of patients with rare and chronic conditions, against the AHCA and Better Care Reconcilliation Act (HR 1628); support for Alexandar-Murray Market Stabilization legislation; supported HR 2077, Restoring the Patients Voice Act

health care reform and the needs of patients with rare and chronic conditions, against the AHCA and Better Care Reconcilliation Act (HR 1628); support for Alexandar-Murray Market Stabilization legislation; supported HR 2077, Restoring the Patients Voice Act

HR 1600, The Patients' Access to Treatment Act - a bill that states that insurance companies cannot charge more for the drugs that they place on specialty tiers than they charge for the drugs on their non-preferred brand tier, designed to protect patients with chronic and expensive conditions from increase percentage cost sharing by insurers; HR 3742 - The Access to Marketplace Insurance Act - a bill that states that adds nonprofits to a list of entities that insurance companies on the exchange must accept premium assistance from, designed to allow patients with chronic and expensive disorders to afford quality insurance; biosimilar implementation - concerned that new rules regarding biosimilar approval offer proper patient protections.

HR 1600, The Patients' Access to Treatment Act - a bill that states that insurance companies cannot charge more for the drugs that they place on specialty tiers than they charge for the drugs on their non-preferred brand tier, designed to protect patients with chronic and expensive conditions from increase percentage cost sharing by insurers; HR 3742 - The Access to Marketplace Insurance Act - a bill that states that adds nonprofits to a list of entities that insurance companies on the exchange must accept premium assistance from, designed to allow patients with chronic and expensive disorders to afford quality insurance; biosimilar implementation - concerned that new rules regarding biosimilar approval offer proper patient protections.

HR 1600, The Patients' Access to Treatment Act - a bill that states that insurance companies cannot charge more for the drugs that they place on specialty tiers than they charge for the drugs on their non-preferred brand tier, designed to protect patients with chronic and expensive conditions from increase percentage cost sharing by insurers; HR 3742 - The Access to Marketplace Insurance Act - a bill that states that adds nonprofits to a list of entities that insurance companies on the exchange must accept premium assistance from, designed to allow patients with chronic and expensive disorders to afford quality insurance; biosimilar implementation - concerned that new rules regarding biosimilar approval offer proper patient protections.

HR 1600, The Patients' Access to Treatment Act - a bill that states that insurance companies cannot charge more for the drugs that they place on specialty tiers than they charge for the drugs on their non-preferred brand tier, designed to protect patients with chronic and expensive conditions from increase percentage cost sharing by insurers; HR 3742 - The Access to Marketplace Insurance Act - a bill that states that adds nonprofits to a list of entities that insurance companies on the exchange must accept premium assistance from, designed to allow patients with chronic and expensive disorders to afford quality insurance; biosimilar implementation - concerned that new rules regarding biosimilar approval offer proper patient protections.

HR 1600, The Patients' Access to Treatment Act - a bill that states that insurance companies cannot charge more for the drugs that they place on specialty tiers than they charge for the drugs on their non-preferred brand tier, designed to protect patients with chronic and expensive conditions from increase percentage cost sharing by insurers; HR 3742 - The Access to Marketplace Insurance Act - a bill that states that adds nonprofits to a list of entities that insurance companies on the exchange must accept premium assistance from, designed to allow patients with chronic and expensive disorders to afford quality insurance; biosimilar implementation - concerned that new rules regarding biosimilar approval offer proper patient protections.

HR 1600, The Patients' Access to Treatment Act - a bill that states that insurance companies cannot charge more for the drugs that they place on specialty tiers than they charge for the drugs on their non-preferred brand tier, designed to protect patients with chronic and expensive conditions from increase percentage cost sharing by insurers; HR 3742 - The Access to Marketplace Insurance Act - a bill that states that adds nonprofits to a list of entities that insurance companies on the exchange must accept premium assistance from, designed to allow patients with chronic and expensive disorders to afford quality insurance; biosimilar implementation - concerned that new rules regarding biosimilar approval offer proper patient protections.

HR 1600 The Patients' Access to Treatment Act - states that an insurance company cannot charge more for drug placed on specialty tier than drug placed in non-preferred brand tier; HR 2624 the Part D Beneficiaries Appeals Act creates an appeals process in Medicare Part D for drugs that are placed on Specialty Tiers; potential legislation regarding access for those with hemophilia to skilled nursing facilities; raised awareness regarding CMS rule that is allowing insurance companies to deny third party nonprofits to pay premiums for those with chronic and rare disorders

HR 1600 The Patients' Access to Treatment Act - states that an insurance company cannot charge more for drug placed on specialty tier than drug placed in non-preferred brand tier

HR 1600 The Patients' Access to Treatment Act - states that an insurance company cannot charge more for drug placed on specialty tier than drug placed in non-preferred brand tier; HR 2624 the Part D Beneficiaries Appeals Act creates an appeals process in Medicare Part D for drugs that are placed on Specialty Tiers; potential legislation regarding access for those with hemophilia to skilled nursing facilities; raised awareness regarding CMS rule that is allowing insurance companies to deny third party nonprofits to pay premiums for those with chronic and rare disorders

HR 1600 The Patients' Access to Treatment Act - states that an insurance company cannot charge more for drug placed on specialty tier than drug placed in non-preferred brand tier; HR 2624 the Part D Beneficiaries Appeals Act creates an appeals process in Medicare Part D for drugs that are placed on Specialty Tiers; potential legislation regarding access for those with hemophilia to skilled nursing facilities; raised awareness regarding CMS rule that is allowing insurance companies to deny third party nonprofits to pay premiums for those with chronic and rare disorders

HR 1600 The Patients' Access to Treatment Act - states that an insurance company cannot charge more for drug placed on specialty tier than drug placed in non-preferred brand tier; HR 2624 the Part D Beneficiaries Appeals Act creates an appeals process in Medicare Part D for drugs that are placed on Specialty Tiers; potential legislation regarding access for those with hemophilia to skilled nursing facilities; raised awareness regarding CMS rule that is allowing insurance companies to deny third party nonprofits to pay premiums for those with chronic and rare disorders

HR 1600 The Patients' Access to Treatment Act - states that an insurance company cannot charge more for drug placed on specialty tier than drug placed in non-preferred brand tier; HR 2624 the Part D Beneficiaries Appeals Act creates an appeals process in Medicare Part D for drugs that are placed on Specialty Tiers; potential legislation regarding access for those with hemophilia to skilled nursing facilities; raised awareness regarding CMS rule that is allowing insurance companies to deny third party nonprofits to pay premiums for those with chronic and rare disorders

HR 1600 The Patients' Access to Treatment Act - states that an insurance company cannot charge more for drug placed on specialty tier than drug placed in non-preferred brand tier; HR 2624 the Part D Beneficiaries Appeals Act creates an appeals process in Medicare Part D for drugs that are placed on Specialty Tiers; potential legislation regarding access for those with hemophilia to skilled nursing facilities; raised awareness regarding CMS rule that is allowing insurance companies to deny third party nonprofits to pay premiums for those with chronic and rare disorders

HR 460 The Patients' Access to Treatment Act - states that an insurance company cannot charge more for drug placed on specialty tier than drug placed in non-preferred brand tier; HR 2827, the Part D Beneficiaries Appeals Fairness Act which provides for an appeals process in Medicare Part D for drugs that are placed on specialty tiers; Restor funding for the National Center for Birth Defects and Developmental Disorders

H.R. 460 Patients' Access to Treatments Act of 2013 - Amends the Public Health Service Act to establish cost-sharing limits for health plans that cover prescription drugs and use a formulary or other tiered cost-sharing structure.

*H.R.460, Patients' Access to Treatments Act of 2013, to establish cost-sharing limits for health plans that cover prescription drugs and use a formulary or other tiered cost-sharing structure. *CMS Interim Final Rule, Patient Protection and Affordable Care Act; Third Party Payment of Qualified Health Plan Premiums, to clarify the rule so patients affected by a bleeding disorder can receive assistance from all qualified third-party payers. *...cont'd*CDC request. A request to stop cuts and/or increase funding to the CDC's (Centers for Disease Control and Prevention) program called N.C.B.D.D.D. (National Center for Birth Defects & Developmental Disabilities). The N.C.B.D.D.D. conducts research of great benefit to persons with a bleeding disorder.

HR 460- Patients access to treatment act bill that states that insurance companies cannot charge more for the drugs that they place on specialty tiers than they charge for the drugs on their non-preferred brand tier, designed to protect patients with chronic and expensive conditions from increase percentage cost sharing by insurers;

HR 460 The Patients' Access to Treatment Act - states that an insurance company cannot charge more for drug placed on specialty tier than drug placed in non-preferred brand tier; HR 2827, the Part D Beneficiaries Appeals Fairness Act which provides for an appeals process in Medicare Part D for drugs that are placed on specialty tiers; Restor funding for the National Center for Birth Defects and Developmental Disorders